This enhancement increased the number of tumor‐infiltrating T cells and exhibited a significant synergistic effect with PD‐L1 blocking antibodies in tumor clearance.[100] The impact of tumor‐colonizing bacteria on the tumor immune microenvironment had been extensively summarized in published reviews.[14d] However, there is currently limited evidence directly linking microbiome‐metabolism‐immune interactions to KRAS mutations, highlighting the need for further research in this area. The gene discussed is KRAS; the disease is neoplasm.